Evaxion picks gonorrhea as second target for vaccine candidate

Encouraging pre-clinical results for Evaxion’s EVX-BV2 candidate have led the firm to add a second target indication, gonorrhea.

Lars Staal Wegner, CEO of Evaxion Biotech | Photo: Evaxion Biotech / PR

Evaxion Biotech has announced that the firm has chosen sexually transmitted disease gonorrhea as the second target of its EVX-B2 vaccine candidate.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs